Yahoo · Oct 22, 2026
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
Roche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipeline advances.
NR
NASDAQ · NRIX
Nurix Therapeutics, Inc.
Healthcare · Biotechnology
$26.80
Down-$0.32 (-1.18%)
Updated Oct 31, 2026, 7:08 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.47B
- P/E ratio
- -6.56
- Dividend yield
- 0.00%
- 52-week range
- $11.50 – $28.23
- Volume
- 2.31M
- Avg. volume
- 1.68M
Price performance · NRIX
NRIX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NRIX closed at $26.80 after 21 trading sessions, up 16.57% for the selected period.
- Last close
- $26.80
- Period change
- +16.57%
- Period low
- $22.13
- Period high
- $27.26
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $26.90 | $26.915 | $25.97 | $26.80 | 2.31M |
| Oct 29, 2026 | $27.46 | $27.99 | $26.685 | $27.12 | 2.38M |
| Oct 28, 2026 | $26.26 | $27.28 | $25.45 | $27.26 | 1.96M |
| Oct 27, 2026 | $25.52 | $27.05 | $25.13 | $26.70 | 2.56M |
| Oct 26, 2026 | $25.35 | $25.82 | $25.03 | $25.55 | 2.34M |
| Oct 23, 2026 | $25.22 | $25.49 | $24.775 | $25.34 | 1.91M |
| Oct 22, 2026 | $25.86 | $26.225 | $25.1801 | $25.51 | 1.93M |
| Oct 21, 2026 | $26.00 | $26.31 | $25.80 | $26.02 | 2.93M |
| Oct 20, 2026 | $24.92 | $26.34 | $24.71 | $26.10 | 3.98M |
| Oct 19, 2026 | $24.57 | $25.29 | $24.3837 | $24.93 | 3.06M |
| Oct 16, 2026 | $24.89 | $25.355 | $24.265 | $24.42 | 4.32M |
| Oct 15, 2026 | $23.67 | $25.135 | $23.61 | $24.95 | 3.75M |
| Oct 14, 2026 | $22.012 | $24.01 | $21.40 | $23.67 | 3.82M |
| Oct 13, 2026 | $22.16 | $23.24 | $21.75 | $22.13 | 4.68M |
| Oct 12, 2026 | $22.27 | $22.575 | $22.025 | $22.16 | 2.85M |
| Oct 9, 2026 | $22.04 | $23.23 | $21.23 | $22.35 | 1.53M |
| Oct 8, 2026 | $22.49 | $22.60 | $21.55 | $22.21 | 2.34M |
| Oct 7, 2026 | $22.43 | $23.10 | $22.18 | $22.73 | 1.63M |
| Oct 6, 2026 | $23.06 | $23.06 | $22.10 | $22.60 | 1.15M |
| Oct 5, 2026 | $22.81 | $23.3066 | $22.425 | $22.88 | 1.01M |
| Oct 2, 2026 | $23.72 | $23.745 | $22.85 | $22.99 | 815.51K |
Latest NRIX news
The latest Smart Investors Daily articles mentioning NRIX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NRIX research
Overview
Company profile and research snapshot.
Company profile
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.78
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 16, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 13, 2026 | Truist Securities | Buy | — |
| Oct 13, 2026 | RBC Capital | Outperform | — |
| Oct 13, 2026 | Oppenheimer | Outperform | — |
| Oct 13, 2026 | Baird | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
What Nurix Therapeutics Stock's Profit Turnaround Means For Shareholders
Nurix Therapeutics reported third quarter 2026 revenue of US$673.06 million and net income of US$549.81 million, with both basic and diluted earnings per share from continuing operations turning positive compared with losses a year earlier. The nine month results to August 31, 2026 show revenue of US$688.36 million and net income of US$373.1 million, indicating that profitability now reflects a longer stretch of the year rather than a single quarter spike. We will examine how Nurix...
Benzinga · Oct 16, 2026
SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts raised targets for MSTR, FOXA, NRIX, ZETA and TWLO, while cutting targets for CAMT and DVN.
Benzinga · Oct 16, 2026
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
